NASDAQ
09.01.26 | 21:57
5,140 US-Dollar
-1,72 % -0,090
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Sa | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 | 340 | GlobeNewswire (Europe) | Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase... ► Artikel lesen | |
| 18.12.25 | BTIG stuft Foghorn Therapeutics mit "Buy" ein - Potenzial in der Krebs-Pipeline | 1 | Investing.com Deutsch | ||
| 18.12.25 | BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline | 1 | Investing.com | ||
| 04.12.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target | 1 | Investing.com | ||
| 07.11.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | Foghorn Therapeutics GAAP EPS of -$0.25 beats by $0.08, revenue of $8.15M beats by $1.95M | 6 | Seeking Alpha | ||
| 05.11.25 | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.10.25 | Foghorn advances protein degrader programs for cancer treatment | 1 | Investing.com | ||
| 30.10.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs | 218 | GlobeNewswire (Europe) | - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors... ► Artikel lesen | |
| 30.10.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.10.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit | 130 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 05.08.25 | Foghorn: EPS übertrifft Schätzungen um 0,07 $ - Umsatz besser als erwartet | 1 | Investing.com Deutsch | ||
| 05.08.25 | Foghorn Therapeutics reports Q2 results | 3 | Seeking Alpha | ||
| 05.08.25 | Foghorn Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.08.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.08.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update | 304 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track... ► Artikel lesen | |
| 25.03.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting | 198 | GlobeNewswire (Europe) | - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Oral presentation on preclinical... ► Artikel lesen | |
| 06.03.25 | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook | 202 | GlobeNewswire (Europe) | First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| ALUMIS | 19,550 | +7,59 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 34,580 | -2,87 % | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/... ► Artikel lesen | |
| ERASCA | 6,705 | +14,81 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| AVIDITY BIOSCIENCES | 72,39 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 66,31 | +3,11 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ARS PHARMACEUTICALS | 13,130 | +19,91 % | ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating | ||
| COGENT BIOSCIENCES | 35,330 | -0,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,820 | +6,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
Das Unternehmen FOGHORN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,140 Euro und damit -1,72 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.